Oncotelic Therapeutics, Inc. Adjustments to Additional Paid in Capital, Convertible Debt with Conversion Feature
Oncotelic Therapeutics, Inc. (OTLC) reported Adjustments to Additional Paid in Capital, Convertible Debt with Conversion Feature of $78.03 thousand for the 3-month period ending 2024-03-31, per its 10-Q filed 2025-05-15.
Financial Statements › Shareholders' Equity › Adjustments to Additional Paid in Capital
us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature · last filed 2025-05-15
- Oncotelic Therapeutics, Inc. adjustments to additional paid in capital, convertible debt with conversion feature for the quarter ending 2024-03-31 was $78.03K.
- Oncotelic Therapeutics, Inc. adjustments to additional paid in capital, convertible debt with conversion feature for the quarter ending 2022-06-30 was $570.72K.
- Oncotelic Therapeutics, Inc. adjustments to additional paid in capital, convertible debt with conversion feature for the quarter ending 2021-03-31 was $605.72K.
- Oncotelic Therapeutics, Inc. adjustments to additional paid in capital, convertible debt with conversion feature for the quarter ending 2020-09-30 was $632.19K, a 261.25% increase year-over-year.
- Oncotelic Therapeutics, Inc. adjustments to additional paid in capital, convertible debt with conversion feature for fiscal 2022 was $570.72K, a 41.15% decline from fiscal 2021.
- Oncotelic Therapeutics, Inc. adjustments to additional paid in capital, convertible debt with conversion feature for fiscal 2021 was $969.75K, a 33.89% increase from fiscal 2020.
- Oncotelic Therapeutics, Inc. adjustments to additional paid in capital, convertible debt with conversion feature for fiscal 2020 was $724.28K.
| Period end | Adjustments to Additional Paid in Capital, Convertible Debt with Conversion Feature 3 month | Adjustments to Additional Paid in Capital, Convertible Debt with Conversion Feature 6 month | Adjustments to Additional Paid in Capital, Convertible Debt with Conversion Feature 12 month |
|---|---|---|---|
| 2024-03-31 | $78.03K 10-Q · filed 2025-05-15 | ||
| 2022-12-31 | $570.72K 10-K · filed 2024-04-12 | ||
| 2022-06-30 | $570.72K 10-Q · filed 2023-11-14 | ||
| 2021-12-31 | $969.75K 10-K/A · filed 2023-04-20 | ||
| 2021-03-31 | $605.72K 10-Q · filed 2022-11-18 | ||
| 2020-12-31 | $724.28K 10-K · filed 2022-04-15 | ||
| 2020-09-30 | $632.19K 10-Q · filed 2021-11-22 | ||
| 2019-09-30 | $175.00K 10-Q · filed 2020-11-16 | $684.14K derived: sum of 2 quarters · filed 2020-11-16 | |
| 2019-06-30 | $509.14K 10-Q · filed 2019-08-19 |